CA9 and breast cancer: After BCG therapy, BC recurrence was associated with elevated levels of specific proteins (ANG, APOE, A1AT, CA9, MMP9, MMP10, PAI1, SDC1, VEGFA) in the OncuriaTM panel, demonstrating its potential for assessing the effectiveness of intravesical BCG treatment and predicting relapse risk in BC patients [22].